↓ Skip to main content

Dove Medical Press

EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer

Overview of attention for article published in International Journal of Nanomedicine, August 2017
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
57 Dimensions

Readers on

mendeley
85 Mendeley
Title
EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer
Published in
International Journal of Nanomedicine, August 2017
DOI 10.2147/ijn.s143293
Pubmed ID
Authors

Yang Li, Yanhong Duo, Shiyun Bao, Lisheng He, Kai Ling, Jinfeng Luo, Yue Zhang, Hao Huang, Han Zhang, Xiaofang Yu

Abstract

DM1, a maytansine derivative, is a highly potential cytotoxic agent but with severe side effects; therefore, its application in clinical cancer therapy is limited. Here, in order to mitigate this intrinsic drawback of DM1, we developed mesoporous silica nanoparticles (MSNs) loaded with DM1 and surface-decorated with hydrochloride dopamine (PDA), polyethylene glycol (PEG), and epithelial cell adhesion molecule (EpCAM) aptamer (APt) for the targeted treatment of colorectal cancer (CRC). In this system, the PDA coating could be used as pH-sensitive gatekeepers to control the release of DM1 from MSNs in response to the pH stimulus and EpCAM APt-guided active targeting enables the increased delivery of DM1 to CRC as well as a reduction in toxicity and side effects by minimizing the exposure of normal tissues to DM1. Results demonstrated that DM1 inhibited the formation of microtubules and induced apoptosis in tumor cells via caspase signaling. In comparison with the control groups, the MSNs-DM1@PDA-PEG-APt bioconjugates exhibited increased binding ability and much higher cytotoxicity to the CRC SW480 cell line. Furthermore, in vivo assays confirmed the advantages of such a strategy. These findings suggested that MSNs-DM1@PDA-PEG-APt could represent a promising therapeutic platform for EpCAM-positive CRC.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 85 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 18%
Student > Master 15 18%
Student > Ph. D. Student 11 13%
Student > Doctoral Student 4 5%
Student > Bachelor 3 4%
Other 6 7%
Unknown 31 36%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 12 14%
Biochemistry, Genetics and Molecular Biology 9 11%
Chemistry 4 5%
Materials Science 4 5%
Agricultural and Biological Sciences 3 4%
Other 11 13%
Unknown 42 49%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2017.
All research outputs
#22,764,772
of 25,382,440 outputs
Outputs from International Journal of Nanomedicine
#3,598
of 4,122 outputs
Outputs of similar age
#287,031
of 327,503 outputs
Outputs of similar age from International Journal of Nanomedicine
#86
of 99 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,122 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.